Dhara Dave MD, John Kimbugwe MD, Randa Hazam MD, Saria Tasnim MD, Manish Patel MPH, MD
The BCR-ABL tyrosine kinase inhibitor dasatinib is a potent treatment for chronic myeloid leukemia (CML). However, it is associated with pulmonary toxicities. Commonly reported dasatinib related pulmonary toxicities include pleural effusion, lung parenchymal abnormalities, and pulmonary hypertension. Diffuse alveolar hemorrhage (DAH) during treatment with dasatinib is very rare. To the best of our knowledge there are only two cases reported. Here we report a 57-year-old Caucasian woman who developed acute hypoxic respiratory failure while on dasatinib for treatment of CML. She was diagnosed with DAH suspected to be secondary to dasatinib, after other common etiologies were ruled out. There was full recovery after stopping dasatinib and treatment with corticosteroids.
Keywords: Dasatinib, pulmonary toxicity, diffuse alveolar hemorrhage, chronic myeloid leukemia
Article citation: Dave D, Kimbugwe J, Hazam R, Tasnim S, Patel M. Dasatinib-induced diffuse alveolar hemorrhage. The Southwest Respiratory and Critical Care Chronicles 2021;9(41):54–57
From: Department of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas
Submitted: 7/7/2021
Accepted: 9/30/2021
Reviewer: Kenneth Nugent MD
Conflicts of interest: none
This work is licensed under a Creative Commons
Attribution-ShareAlike 4.0 International License.